

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Ortho Regenerative Technologies Inc. (the “Issuer”)**

Trading Symbol: **ORTH**

Number of Outstanding Listed Securities: **24,712,424**

Date: **October 5th,2018**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.
- **The Corporation continues its business objectives as to its pre-clinical development plan and patent prosecution for its four families.**

2. Provide a general overview and discussion of the activities of management.

In the period, Management's primary focus was to (i) continue to raise capital (ii) pursue the activities leading to our pre-clinical development path and manufacturing process (iii) maintain various discussions with well-known contract research organizations for our phase I/II humans' trials.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Nothing applicable during the period.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Nothing applicable during the period.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

During the period the Corporation entered into an agreement with a leading Contract Manufacturing Organization ("CMO") within the global biopharmaceutical industry to commence work on providing the Corporation with current good manufacturing practice ("cGMP") finished dosage form quantities of Ortho-R for currently planned clinical trials and strategic partnering initiatives.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Nothing applicable during the period.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

8. Describe the acquisition of new customers or loss of customers.

Nothing applicable during the period.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

10. **Nothing applicable during the period.**

11. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

Nothing applicable during the period.

12. Report on any labour disputes and resolutions of those disputes if applicable.

Nothing applicable during the period.

13. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Nothing applicable during the period.

14. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Nothing applicable during the period.

15. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Common shares	N/A	N/A	N/A
Warrants	N/A	N/A	N/A
Options	465,000	Sept. 18, 2018 Exercise price @ \$0.50 per share. Vesting 25% immediately and the balance equally over the next 3 years. 5 year option life from date of grant.	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

16. Provide details of any loans to or by Related Persons.

No new loans with related parties in the current period

17. Provide details of any changes in directors, officers or committee members.

On September 19th the Corporation announced that Luc Mainville was appointed Chief Financial Officer, succeeding Benedek Simo who remains as Corporate Controller.

18. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None in the current period.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: October 5th, 2018

Ortho Regenerative Technologies Inc.
/s/ Luc Mainville
Senior VP & Chief Financial Officer
Official Capacity

Issuer Details Name of Issuer Ortho Regenerative Technologies Inc.	For Month End September 2018	Date of Report YY/MM/D 2018/10/05
Issuer Address 166667, Boul. Hymus,		
City/Province/Postal Code Kirkland, Quebec, H9H 4R9	Issuer Fax No. 514.694.0443	Issuer Telephone No. 514.694.0865
Contact Name Luc Mainville	Contact Position VP Finance & CFO	Contact Telephone No. (514) 694-0150
Contact Email Address mainville@orthorti.com	Web Site Address www.orthorti.com	